Noninvasive prenatal testing, also called cell-free DNA screening or NIPT, is the one prenatal line item where the number you are quoted and the number you are billed can differ by a factor of ten. That is not an accident. The labs that run these tests operate two parallel price lists: a list price they submit to insurers, and a self-pay or prompt-pay price they will honor if you ask for it before the sample goes in.
This guide prices both, using each lab’s own published billing page read on September 5, 2026, plus the 2026 Medicare fee schedule and 2024 national claims data as the government benchmark. It covers cost and billing navigation only. Whether to screen, and which panel to run, is a conversation for your clinician.
What Does an NIPT Test Cost Without Insurance?
| Service / Type | Low | Average | High |
|---|---|---|---|
| Natera Panorama prompt-pay cash price | $249 | n/a | $349 |
| Natera income-based assistance price | $0 | n/a | $239 |
| Myriad income-based assistance tiers | $0 | n/a | $249 |
| Quest QNatal Advanced, patient cap after a plan denial | n/a | n/a | $299 |
| California Prenatal Screening Program cfDNA fee (state-set) | n/a | $344 | n/a |
| Medicare CLFS rate, CPT 81420 (2026) | n/a | $759.05 | n/a |
| Medicare CLFS rate, CPT 81507 (2026) | n/a | $795.00 | n/a |
| Average billed charge, CPT 81420 (2024 Medicare claims) | n/a | $2,063 | n/a |
| Average billed charge, CPT 81507 (2024 Medicare claims) | n/a | $1,472 | n/a |
The government rows are the cleanest benchmark available. The CY2026 Q3 Clinical Laboratory Fee Schedule, effective January 1, 2026, sets 81420 at $759.05, 81422 (microdeletions) at $759.05 and 81507 at $795.00. Against that, the CMS national claims file for 2024, released May 2026, shows labs submitting an average charge of $2,063.23 for 81420 while Medicare allowed $743.73, and $1,472.31 for 81507 against $779.10 allowed. Those are thin samples (150 services for 81420 and 13 for 81507, since Medicare beneficiaries are rarely pregnant), so treat them as evidence of the billed-to-allowed gap rather than a national average for the whole market.
That gap, roughly 2.8 to 1, is the entire reason NIPT generates surprise bills. Nobody actually collects $2,063. But if a claim is denied and the balance falls to you, $2,063 is the number on the letter.
What Drives the Price
Whether you ask for the cash price before or after the test runs. Natera states that it offers a prompt-pay cash price at the time of testing, typically $249 or $349 depending on the test, and that when you provide insurance information it will estimate your out-of-pocket cost and message you only if that estimate exceeds the cash price. In other words, the cash price is a live option you have to reach for. After the claim is adjudicated you are negotiating a bill rather than buying a test.
Which lab your OB’s office happens to use. The prices above are not interchangeable products marketed at similar prices. They are five different commercial policies. Quest states that 79% of QNatal Advanced patients pay less than $99, that insured patients with coverage and appropriate diagnosis codes can pay as little as $0, and that a patient whose plan denies the test as a noncovered service should pay no more than $299. Quest also references an uninsured patient price available in all states for qualified patients, without publishing the amount. Myriad’s assistance program prices eligible tests at $0, $100 or $249 depending on household income, and offers interest-free payment plans starting at $15 a month. Labcorp, which runs MaterniT 21 PLUS and MaterniT GENOME, publishes no price at all and routes patients to an online cost estimator and a dedicated billing line.
The size of the panel. A basic trisomy 13, 18 and 21 screen bills under 81420 or 81507. Adding microdeletion screening pulls in 81422 at the same CLFS rate, and bundling carrier screening or single-gene panels adds separate codes again. Each add-on is a separate line on the claim and a separate opportunity for a denial.
Where you live. California operates the most consequential state program in the country. CDPH’s Prenatal Screening Program sets one statewide fee, currently $344 for cfDNA screening and $85 for MSAFP, and requires Medi-Cal and private insurance to cover all program fees with no copayment, coinsurance or deductible, except for self-insured employers and out-of-state plans. If you are uninsured or your plan falls under an exception, CDPH says you are billed the program fee directly, which effectively makes $344 the state’s self-pay price. Worth knowing: CDPH’s own program pages disagree with each other. The main program page and the patient information page still carry the older “$232 for cfDNA, increasing to $344 on July 1, 2024” language, while the billing FAQ states the fee is $344 today. The date has passed, so $344 is the operative number, but do not be surprised if a clinic quotes you the stale one.
Whether the pregnancy is coded as high risk. Diagnosis codes drive coverage more than the test does. Quest is explicit that appropriate ICD-10 codes are what move an insured patient toward $0. ACOG’s January 2026 practice advisory holds that screening should be offered to all pregnant patients regardless of age or risk, but plan coverage policy and clinical guidance are two different documents, and the claim is adjudicated against the plan’s.
Cash Price vs. Insurance
This is one of the clearest cases on this site where handing over an insurance card can cost you money. If you have a high deductible you have not met, the lab bills the list price, your plan applies the whole allowed amount to your deductible, and you owe several hundred dollars for a test you could have bought outright for $249.
The labs know this and are surprisingly candid about it. Natera commits to messaging you when its estimate of your out-of-pocket cost exceeds its prompt-pay cash price, and says over 60% of patients with in-network insurance have no out-of-pocket cost. Both of those things can be true at once: if you are in network with a met deductible, use the insurance. If you are uninsured, underinsured, or early in a deductible year, ask for the cash price and decline the insurance billing.
One caution about reading these pages. Natera’s own billing page contradicts itself on the assistance floor: the rendered page says financial assistance can reduce a patient’s cost to “$0 to $239 per test,” while the structured FAQ data embedded in the same page says “$149 or less.” We publish both because both appear on the page as read on September 5, 2026. Get any assistance figure confirmed in writing before you rely on it.
If a bill has already arrived, treat it as an opening offer. Ask the lab in writing for its self-pay or prompt-pay rate and for the difference to be rebilled at that rate, and use the language in our guide to negotiating medical bills and the negotiation script tool. Labs settle these routinely because the alternative is collections on an account that was never going to pay list.
How to Pay Less
Ask for the cash price before the blood draw, in writing. This is the whole ballgame. The prompt-pay price at Natera is $249 or $349; the assistance tiers at Myriad are $0, $100 and $249. Both are available at the time of testing and much harder to get afterward. Ask the ordering office which lab it sends to, then call that lab directly.
Get a cost estimate from the lab, not the clinic. Natera, Labcorp and Quest all run pre-test estimate programs. The clinic does not know the lab’s contract with your plan; the lab does. Ten minutes on the phone before the draw is worth several hundred dollars.
Apply for the income-based program even if you think you earn too much. Myriad’s tiers are set by household size and income and reach $249 well up the income scale. Natera’s program runs to $0. These are not charity-of-last-resort programs, they are standard commercial pricing policy.
Check whether your state runs a program. California’s $344 statewide fee is cheaper than most list prices and comes with mandated coverage for insured patients. Other states have their own rules, and the state Medicaid program is the first place to check if you are uninsured.
Do not pay the list price on a denial. Quest caps patient responsibility at $299 after a noncovered denial. If a lab bills you $1,500 after a denial, that is a policy question, not a math question. Ask for the denial-price policy in writing, and if the account has already moved, our guides to reading an itemized hospital bill and handling medical bills in collections cover the next steps. You can also sanity-check any quote against the ranges above with our fair price checker.
Budget for what a positive screen triggers. ACOG’s guidance is that a positive cfDNA result should be followed by genetic counseling, comprehensive ultrasound and an opportunity for diagnostic testing. Each of those is billed separately. Our guides to ultrasound costs without insurance and genetic testing costs cover what the follow-up looks like on a cash basis.
The Bottom Line
Plan on $249 to $349 if you buy NIPT as a cash payer and ask for the price up front, less if you qualify for a lab’s income-based tier, and $344 if you are in California and going through the state program. The $1,500 to $2,100 figures circulating online are billed charges, not prices anyone actually pays, and no self-pay patient should ever settle one.
The order of operations matters more here than the dollar amount. Find out which lab the sample is going to, call that lab, ask for the self-pay price and the assistance application, and decide whether to run it through insurance only after you know both numbers. While you are pricing the rest of the pregnancy, our guides to prenatal care costs, childbirth without insurance and C-section costs cover the larger bills coming later.